Table 3

Independent predictors of the primary endpoint of death, non-fatal myocardial infarction, prolonged ventricular arrhythmia or hospitalisation with unstable angina or heart failure

HR (95% CI)*p Value
Final model with new hyperenhancement as a categorical variable:
Presence of new hyperenhancement (y/n)3.11 (1.43 to 6.77)0.004
Addition of extra variables:†
    LVEF after revascularisation (%)0.98 (0.95 to 1.02)0.31
    Troponin after revascularisation (μg/l)1.02 (0.96 to 1.08)0.52
    Troponin after revascularisation >0.2 μg/l‡1.26 (0.33 to 4.73)0.73
    PMI1.36 (0.46 to 4.03)0.57
    All other variables from table 2>0.10
Final model with new hyperenhancement as a continuous variable:
New hyperenhancement (g)1.10 (1.03 to 1.17)0.005
Addition of extra variables:¶
    LVEF after revascularisation (%)0.99 (0.95 to 1.02)0.49
    Troponin after revascularisation (μg/l)1.01 (0.96 to 1.07)0.71
    Troponin after revascularisation >0.2 μg/l1.25 (0.43 to 3.61)0.68
    PMI1.58 (0.58 to 4.41)0.88
    All other variables from table 2>0.10

  • *All models were adjusted for age and sex.

  • †After inclusion of each of the extra variables, HR for new hyperenhancement remained >2.6 with p value <0.05.

  • ‡0.2 μg/l equals the 99th centile of the lower limit of quantification.

  • ¶After inclusion of each of the extra variables, HR for new hyperenhancement (continuous) remained >1.08 with p value <0.05.

  • LVEF, denotes left ventricular ejection fraction; PMI, procedure-related myocardial infarction according to the ESC/ACC/AHA/WHF guidelines.